Vaccines Market Research

Vaccines Market Research Reports & Industry Analysis

10 January 2020
Pharma
Vaccines Market Research

The global vaccine market is a steady grower, while also providing an absolutely vital medical service to billions of people around the world.  This makes the vaccines market a strong candidate for investment, as long as a company understands the risks involved.  This is what Visiongain specializes in.  We do in-depth vaccine market research, along with many other industries, to bring you the information needed to make strong decisions.

Our reports touch on many areas of the topic; here is a brief summary of the current state of the vaccine market research.

Vaccines Overview

Vaccines specifically formulated substances that improve human immunity to a variety of diseases.  Each vaccine is tailored to a specific disease, usually utilizing a dead or dormant form of that disease to train the body's immune system to fight it.  Currently, the primary market segmentations are for live attenuated vaccines, inactivated vaccines, and subunit/recombinant vaccines. 

Vaccines Market Global Outlook

On the whole, the vaccine market shows a growth rate of approximately 6.67% and is forecasted to remain there until the mid-2020s.   Of the various market segments, live attenuated vaccines (which use live, but harmless, disease matter) is by far the most dominant, accounting for the majority of vaccines in use.  The growth in this segment is projected to have a CAGR of 5.44% in the near future.

Of vaccines currently on the market, one strong growth area is in vaccines for the Human Papilloma Virus.  HPV is a mild sexually transmitted disease which is also linked to cervical cancer, and its vaccine being increasingly mandated by world governments.

As such, growth in the vaccine market is seen as largely government-driven.  States implement initiatives mandating vaccination, causing immediate boosts to the industry.  This fuels research into new vaccines, which are then introduced to the market.

Major Challenges to The Global Vaccine Market

Expansion into developing nations has been a continual challenge.  Many governments are at times disinterested in public health initiatives, or else lack the resources to implement widespread vaccination.  There is also a substantial lack of education among the public and some lingering distrust of vaccines themselves. These issues create uncertainty in the ability of the market to grow globally.

In addition, the production of new vaccines is extremely expensive, with long and arduous regulations that must be cleared, slowing the introduction of new products.

Visiongain has far more insights to share.  Click here to browse our selection of pharmaceutical market research.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

Read

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

Read

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

Read

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever